In observance of the Holy Week, the Philippine News Agency’s online news service will be off on March 29, Good Friday, and March 30, Black Saturday. Normal operations will resume on March 31, Easter Sunday.

— The Editors

PH approves EUA of Bharat Biotech’s Covaxin

By Ma. Teresa Montemayor

June 25, 2021, 3:29 pm

<p>Covaxin <em>(Photo courtesy of Bharat Biotech)</em></p>

Covaxin (Photo courtesy of Bharat Biotech)

MANILA – Food and Drug Administration (FDA) Director General Eric Domingo on Friday confirmed the country has granted full emergency use authorization to India-based Bharat Biotech’s Covid-19 vaccine called Covaxin.

Covaxin was earlier given only an EUA conditional on its submission of Good Manufacturing Practices (GMP) certification.

“Nung nakalipas kasi meron pa silang hindi na-submit na certificate sa amin. Bagamat pumasa na raw sila sa inspection sa good manufacturing practice, hindi pa nila na-submit 'yung actual certificate (Earlier there’s a certificate they haven’t submitted. Even though they have passed the good manufacturing practice inspection, they haven’t submitted the actual certificate),” Domingo said in a televised public briefing.

This prohibited Bharat Biotech from importing its Covid-19 vaccine, he added.

Covaxin is an inactivated viral vaccine with an 81 percent efficacy rate. Developed with whole-virion inactivated vero cell-derived technology, it contains inactivated viruses which teach the immune system to prepare a defense mechanism without infecting the person.

“Na-submit nila last week, so ngayon pwede na sila mag-import at pwede na rin gamitin dito sa bansa natin 'yung Covaxin na bago pong vaccine mula sa India (They have submitted the certificate last week, so they can now import and Covaxin, a new vaccine from India, can now be used in our country),” Domingo said.

Apart from Covaxin, the FDA has granted EUA to Pfizer-BioNTech, Oxford–AstraZeneca, Sinovac, Sputnik V, Janssen, Moderna, and Sinopharm.

The Philippines is the ninth country to grant Covaxin an EUA. (PNA)

Comments